公开(公告)号：EP0972519A1

公开(公告)日：2000-01-19

申请号：EP98905773.2

申请日：1998-03-04

申请人： OTSUKA PHARMACEUTICAL CO., LTD.

发明人： JIN, Tienan ,  SUGIURA, Kikuya ,  MORITA, Haruo ,  IKEHARA, Susumu ,  SOGO, Shinji ,  YAMANISHI, Kazuya ,  ADACHI, Masakazu

IPC分类号： A61K35/28 ,  A61K35/14

CPC分类号： C12N5/0647 ,  A61K35/17 ,  A61K35/28 ,  A61K39/001 ,  A61K2035/122 ,  A61K2035/124 ,  C12N5/0648

摘要： This invention provides a novel immunotolerance inducer which is effective in inducing immunological tolerance without involving any remarkable invasive procedure, thus ensuring the maintenance of a transplanted organ without administration of an immunosuppressant drug. This immunotolerance inducer is either a dual-system inducer comprising a first pharmaceutical composition for portal administration which comprises an effective amount of a tolerogen containing hematopoietic stem cells, hematopoietic progenitor cells, mature lymphocytes or a mixture thereof as the active component and a second pharmaceutical composition for intravenous administration which comprises an effective amount of the above-mentioned tolerogen as the active component or a single-system immunotolerance inducer which comprises an effective amount of a tolerogen containing hematopoietic stem cells, hematopoietic progenitor cells or a mixture thereof as an active component, said single-system immunotolerance inducer being administered in association with radiation.

摘要翻译： 本发明提供了一种新颖的免疫耐受诱导剂，其有效诱导免疫耐受而不涉及任何明显的侵入性过程，从而确保维持移植的器官而不施用免疫抑制剂药物。 该免疫耐受诱导剂是包含用于门静脉给药的第一药物组合物的双系统诱导剂，其包含有效量的含有造血干细胞的耐受原体，造血祖细胞，成熟淋巴细胞或其混合物作为活性成分和第二药物组合物 用于静脉内给药，其包含有效量的作为活性成分的上述耐受原或单系免疫耐受诱导剂，其包含有效量的含有造血干细胞的致敏原，造血祖细胞或其混合物作为活性成分， 所述单系统免疫耐受诱导剂与辐射相关联地施用。